SyntIV

Executive Summary

SyntIV LLC is a private biotechnology company based in Cambridge, Massachusetts, founded in 2021. The company leverages synthetic immunology and virology to engineer novel biomolecules, including molecular biosensors, therapeutic biologics, and vaccines. Its core platform focuses on synthetic biology for engineered cell therapies and biologics, with particular expertise in antibodies and T-cell receptors. Although SyntIV is still in early stages with no disclosed pipeline or funding, its innovative approach positions it to address unmet needs in infectious disease, oncology, and autoimmune disorders. The company's ability to create programmable biomolecules could enable rapid response to emerging pathogens and personalized medicine. However, limited public information and lack of validated product candidates present significant uncertainty, warranting a moderate conviction score.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Announcement60% success
• Q4 2026Strategic Partnership with Major Pharma40% success
• Q2 2027Preclinical Proof-of-Concept Data Release50% success